192 related articles for article (PubMed ID: 32817208)
1. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes.
Adams SF; Grimm AJ; Chiang CL; Mookerjee A; Flies D; Jean S; McCann GA; Michaux J; Pak H; Huber F; Neal C; Dangaj D; Bassani-Sternberg M; Rusakiewicz S; Facciabene A; Coukos G; Gimotty PA; Kandalaft LE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817208
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
Brencicova E; Jagger AL; Evans HG; Georgouli M; Laios A; Attard Montalto S; Mehra G; Spencer J; Ahmed AA; Raju-Kankipati S; Taams LS; Diebold SS
PLoS One; 2017; 12(4):e0175712. PubMed ID: 28410380
[TBL] [Abstract][Full Text] [Related]
3. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
Yuan J; Kashiwagi S; Reeves P; Nezivar J; Yang Y; Arrifin NH; Nguyen M; Jean-Mary G; Tong X; Uppal P; Korochkina S; Forbes B; Chen T; Righi E; Bronson R; Chen H; Orsulic S; Brauns T; Leblanc P; Scholler N; Dranoff G; Gelfand J; Poznansky MC
J Hematol Oncol; 2014 Feb; 7():15. PubMed ID: 24565018
[TBL] [Abstract][Full Text] [Related]
4. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
6. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
7. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.
Pisano S; Lenna S; Healey GD; Izardi F; Meeks L; Jimenez YS; Velazquez OS; Gonzalez D; Conlan RS; Corradetti B
Clin Transl Med; 2021 Oct; 11(10):e551. PubMed ID: 34709744
[TBL] [Abstract][Full Text] [Related]
9. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.
Chiriva-Internati M; Yu Y; Mirandola L; Jenkins MR; Chapman C; Cannon M; Cobos E; Kast WM
PLoS One; 2010 May; 5(5):e10471. PubMed ID: 20485677
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell lysates as immunogenic sources for cancer vaccine design.
González FE; Gleisner A; Falcón-Beas F; Osorio F; López MN; Salazar-Onfray F
Hum Vaccin Immunother; 2014; 10(11):3261-9. PubMed ID: 25625929
[TBL] [Abstract][Full Text] [Related]
11. Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17.
Mattila JP; Mirandola L; Chiriva-Internati M
J Biomed Mater Res B Appl Biomater; 2019 Jan; 107(1):29-36. PubMed ID: 29504239
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
13. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
Loercher AE; Nash MA; Kavanagh JJ; Platsoucas CD; Freedman RS
J Immunol; 1999 Dec; 163(11):6251-60. PubMed ID: 10570318
[TBL] [Abstract][Full Text] [Related]
14. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
15. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
19. TRAF3 suppression encourages B cell recruitment and prolongs survival of microbiome-intact mice with ovarian cancer.
Zorea J; Motro Y; Mazor RD; Carmi YK; Shulman Z; Mahajna J; Moran-Gilad J; Elkabets M
J Exp Clin Cancer Res; 2023 May; 42(1):107. PubMed ID: 37121997
[TBL] [Abstract][Full Text] [Related]
20. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
